News & Events about Akebia Therapeutics Inc.
Akebia Therapeutics (NASDAQ:AKBA Get Rating) had its price target increased by equities research analysts at HC Wainwright from $1.25 to $2.00 in a research note issued on Wednesday, The Fly reports. HC Wainwrights price objective indicates a potential upside of 119.20% from the ...
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split PR Newswire CAMBRIDGE, Mass., April 14, 2023 Webcast Scheduled for Friday, April 21 at...
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders PR Newswire CAMBRIDGE, Mass., April 11, 2023 Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass., April 11...
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023 Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023 PR Newswire CAMBRIDGE, Mass., April 7, 2023 CAMBRIDGE, Mass., April 7, 2023...
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting PR Newswire CAMBRIDGE, Mass., March 24, 2023 CAMBRIDGE, Mass., March 24, 2023 /PRNewswire/ -- Akebia...